Amylyx Pharmaceuticals (AMLX) Return on Capital Employed (2022 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Return on Capital Employed of 53.6% for Q1 2026, up 6849.0% year-over-year from 0.77% in Q1 2025, and down 13.63% quarter-over-quarter from 47.17% in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Return on Capital Employed (2022 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 53.6% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 6849.0% year-over-year to 53.6%; the TTM figure through Mar 2026 stood at 53.6% (up 6849.0% YoY), while the FY2025 annual figure was 63.75%, up 3246.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 53.6%, down from 47.17% in the prior quarter.
- The five-year high for Return on Capital Employed was 9.46% in Q4 2023, with the low at 162.43% in Q4 2024.
- The 5-year median for Return on Capital Employed is 62.22% (2025), against an average of 67.12%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 17189 bps in 2024, then surged 11526 bps in 2025.
- Amylyx Pharmaceuticals' Return on Capital Employed stood at 83.95% in 2022, then surged by 111 bps to 9.46% in 2023, then sank by 1816 bps to 162.43% in 2024, then soared by 71 bps to 47.17% in 2025, then slipped by 14 bps to 53.6% in 2026.
- Business Quant data shows AMLX's Return on Capital Employed at 53.6% in Q1 2026, 47.17% in Q4 2025, and 62.22% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.35 Bn | 4.35 Bn | - | -62.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.85% |
| Mar 31, 2026 | -53.60% |
| Dec 31, 2025 | -47.17% |
| Sep 30, 2025 | -62.22% |
| Jun 30, 2025 | -106.06% |
| Mar 31, 2025 | -122.09% |
| Dec 31, 2024 | -162.43% |
| Sep 30, 2024 | -114.58% |
| Jun 30, 2024 | -58.33% |
| Mar 31, 2024 | -21.63% |
| Dec 31, 2023 | 9.46% |
| Sep 30, 2023 | -1.86% |
| Jun 30, 2023 | -22.12% |
| Mar 31, 2023 | -44.70% |
| Dec 31, 2022 | -83.95% |
| Sep 30, 2022 | -108.42% |
| Jun 30, 2022 | -68.84% |
| Mar 31, 2022 | -72.47% |